JPWO2022053703A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022053703A5 JPWO2022053703A5 JP2023516483A JP2023516483A JPWO2022053703A5 JP WO2022053703 A5 JPWO2022053703 A5 JP WO2022053703A5 JP 2023516483 A JP2023516483 A JP 2023516483A JP 2023516483 A JP2023516483 A JP 2023516483A JP WO2022053703 A5 JPWO2022053703 A5 JP WO2022053703A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- component
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 46
- 229960005486 vaccine Drugs 0.000 claims 32
- 241000711975 Vesicular stomatitis virus Species 0.000 claims 25
- 230000000890 antigenic effect Effects 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000003886 Glycoproteins Human genes 0.000 claims 15
- 108090000288 Glycoproteins Proteins 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 230000000174 oncolytic effect Effects 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 8
- 108060003393 Granulin Proteins 0.000 claims 6
- 102000011931 Nucleoproteins Human genes 0.000 claims 6
- 108010061100 Nucleoproteins Proteins 0.000 claims 6
- 102000007982 Phosphoproteins Human genes 0.000 claims 6
- 108010089430 Phosphoproteins Proteins 0.000 claims 6
- 108010046722 Thrombospondin 1 Proteins 0.000 claims 6
- 102100036034 Thrombospondin-1 Human genes 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 2
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims 2
- 229940122985 Peptide agonist Drugs 0.000 claims 2
- 102000002689 Toll-like receptor Human genes 0.000 claims 2
- 241000711973 Vesicular stomatitis Indiana virus Species 0.000 claims 2
- 241000711959 Vesicular stomatitis New Jersey virus Species 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100022144 Achaete-scute homolog 2 Human genes 0.000 claims 1
- 101000901109 Homo sapiens Achaete-scute homolog 2 Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 102000000763 Survivin Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20195872.5 | 2020-09-14 | ||
| EP20195872 | 2020-09-14 | ||
| EP20210671.2 | 2020-11-30 | ||
| EP20210671 | 2020-11-30 | ||
| EP21155814.3 | 2021-02-08 | ||
| EP21155814 | 2021-02-08 | ||
| EP21176373.5 | 2021-05-27 | ||
| EP21176373 | 2021-05-27 | ||
| PCT/EP2021/075184 WO2022053703A1 (en) | 2020-09-14 | 2021-09-14 | Heterologous prime boost vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542297A JP2023542297A (ja) | 2023-10-06 |
| JPWO2022053703A5 true JPWO2022053703A5 (https=) | 2024-09-24 |
| JP2023542297A5 JP2023542297A5 (https=) | 2024-09-24 |
Family
ID=77897647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516483A Pending JP2023542297A (ja) | 2020-09-14 | 2021-09-14 | 異種プライムブーストワクチン |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20220088162A1 (https=) |
| EP (1) | EP4210734A1 (https=) |
| JP (1) | JP2023542297A (https=) |
| KR (1) | KR20230069956A (https=) |
| CN (1) | CN116348137A (https=) |
| AU (1) | AU2021341521A1 (https=) |
| BR (1) | BR112023001864A2 (https=) |
| CA (1) | CA3188236A1 (https=) |
| CL (1) | CL2023000642A1 (https=) |
| CO (1) | CO2023004596A2 (https=) |
| CR (1) | CR20230155A (https=) |
| DO (1) | DOP2023000053A (https=) |
| EC (1) | ECSP23027542A (https=) |
| IL (1) | IL300060A (https=) |
| JO (1) | JOP20230056A1 (https=) |
| MX (1) | MX2023002884A (https=) |
| PE (1) | PE20240492A1 (https=) |
| TW (1) | TW202227126A (https=) |
| WO (1) | WO2022053703A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| DK3429618T5 (da) | 2016-03-16 | 2024-09-16 | Amal Therapeutics Sa | Kombination af en immuncheckpoint-modulator og et kompleks som omfatter et cellepenetrerende peptid, en last og en tlr-peptidagonist til anvendelse i medicin |
| DK3515476T3 (da) | 2016-09-21 | 2024-09-02 | Amal Therapeutics Sa | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2025257278A1 (en) | 2024-06-12 | 2025-12-18 | Boehringer Ingelheim International Gmbh | Immunogenic sequences |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006083301A2 (en) | 2004-06-17 | 2006-08-10 | Medimmune, Inc. | Immunogenic compositions comprising hmgb1 polypeptides |
| DE102004034461B4 (de) | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| ES2291071B1 (es) | 2005-06-13 | 2009-03-16 | Proyecto De Biomedicina Cima, S.L. | Agentes y metodos basados en el uso del dominio eda de la fibronectina. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010004052A2 (en) | 2008-07-11 | 2010-01-14 | Medizinische Universität Innsbruck | Agonists of nr2f6 for immunosuppression |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| DE102008050860A1 (de) | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| US20120237535A1 (en) | 2009-09-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Therapeutic Compositions For The Treatment of HPV-Induced Diseases |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
| WO2012015979A2 (en) | 2010-07-27 | 2012-02-02 | The Regents Of The University Of California | Hmgb1-derived peptides enhance immune response to antigens |
| US9555074B2 (en) | 2010-10-08 | 2017-01-31 | Regents Of The University Of Minnesota | Annexin II compositions |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| EP3130347B1 (en) | 2011-12-30 | 2019-09-18 | Halozyme, Inc. | Ph20 polypeptide variants, formulations and uses thereof |
| WO2013120073A1 (en) | 2012-02-09 | 2013-08-15 | Av Therapeutics, Inc. | Synthetic toll-like receptor-4 (tlr-4) agonist peptides |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| DK3515476T3 (da) * | 2016-09-21 | 2024-09-02 | Amal Therapeutics Sa | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer |
| TWI894135B (zh) * | 2019-01-25 | 2025-08-21 | 德商百靈佳殷格翰國際股份有限公司 | 編碼ccl21之重組棒狀病毒 |
-
2021
- 2021-09-14 JP JP2023516483A patent/JP2023542297A/ja active Pending
- 2021-09-14 US US17/474,240 patent/US20220088162A1/en not_active Abandoned
- 2021-09-14 PE PE2023001150A patent/PE20240492A1/es unknown
- 2021-09-14 IL IL300060A patent/IL300060A/en unknown
- 2021-09-14 KR KR1020237012084A patent/KR20230069956A/ko active Pending
- 2021-09-14 CR CR20230155A patent/CR20230155A/es unknown
- 2021-09-14 CA CA3188236A patent/CA3188236A1/en active Pending
- 2021-09-14 MX MX2023002884A patent/MX2023002884A/es unknown
- 2021-09-14 BR BR112023001864A patent/BR112023001864A2/pt unknown
- 2021-09-14 CN CN202180062772.6A patent/CN116348137A/zh active Pending
- 2021-09-14 AU AU2021341521A patent/AU2021341521A1/en active Pending
- 2021-09-14 EP EP21773815.2A patent/EP4210734A1/en active Pending
- 2021-09-14 WO PCT/EP2021/075184 patent/WO2022053703A1/en not_active Ceased
- 2021-09-14 TW TW110134259A patent/TW202227126A/zh unknown
-
2023
- 2023-03-07 CL CL2023000642A patent/CL2023000642A1/es unknown
- 2023-03-14 DO DO2023000053A patent/DOP2023000053A/es unknown
- 2023-03-14 JO JOJO/P/2023/0056A patent/JOP20230056A1/ar unknown
- 2023-04-13 CO CONC2023/0004596A patent/CO2023004596A2/es unknown
- 2023-04-14 EC ECSENADI202327542A patent/ECSP23027542A/es unknown
-
2025
- 2025-06-13 US US19/237,140 patent/US20250312428A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7097841B2 (en) | Ferritin fusion proteins for use in vaccines and other applications | |
| JP2023002680A5 (https=) | ||
| JPH07502026A (ja) | ウイルス抗体複合体 | |
| JP2012501959A5 (https=) | ||
| JP2015509707A5 (https=) | ||
| JP2012525410A5 (https=) | ||
| JP2020509737A5 (https=) | ||
| US5882650A (en) | Cross-reactive influenza A immunization | |
| JP2024069465A5 (https=) | ||
| JPWO2020206330A5 (https=) | ||
| JPWO2021163438A5 (https=) | ||
| JPWO2022053703A5 (https=) | ||
| JPWO2020061229A5 (https=) | ||
| JPWO2020065349A5 (https=) | ||
| JP2020526202A5 (https=) | ||
| WO2025007890A1 (zh) | 新型疫苗递送体系 | |
| CN117396493A (zh) | 氨基酸、核苷酸和表达它们的载体及其在预防沙贝病毒感染中的用途 | |
| JPWO2021243172A5 (https=) | ||
| JPWO2021205027A5 (https=) | ||
| JPWO2022190018A5 (https=) | ||
| JPWO2023174998A5 (https=) | ||
| JPWO2022129428A5 (https=) | ||
| EP0542895B1 (en) | Cross-reactive influenza a immunization | |
| JPWO2023110983A5 (https=) | ||
| JPWO2021247789A5 (https=) |